RQ Bio’s differentiated approach accelerates the development of potent, resilient and long-lasting antibodies.
We target conserved parts of a key influenza protein whilst preserving high level antibody potency.
Using immune directing vaccination and antibody optimisation, we identify mAbs that preserve virus neutralisation potency and resilience to virus evolution, whilst retaining excellent clinical development properties.
By integrating robust functional assays with developability and biophysical profiling, we confidently identify lead candidates with a high likelihood of clinical success.
Neutralising antibodies play a key role in preventing infection and controlling disease. When potent neutralising antibodies are administered prophylactically, they circumvent the reliance on an individual’s own immune system to protect from serious disease.
RQ Biotechnology aims to tip the balance in favor of the human, by developing potent, evolutionarily advanced neutralising antibodies to target the virus.
